Mild cognitive impairment (MCI) has become an important topic for clinical practice and research. MCI refers to a clinical transitional state between the cognitive changes of aging and the earliest clinical features of dementia. Originally, the construct referred to a memory impairment in the setting of preserved nonmemory cognitive performance and functional abilities, but more recently the term has been expanded to include other cognitive domains besides memory. Most of the literature refers to the amnestic form of MCI, which is likely a precursor of clinical Alzheimer's disease. Much research generated in the past decade on MCI indicates that the criteria are available and reliable and that the outcomes of patients are known. Some predictors of progression have been identified, and others are being evaluated. Neuroimaging studies document the intermediate state of brain structural and functional features in patients with MCI, while neuropathologic data confirm transitional pathologic findings. Several randomized clinical trials have been completed recently, and although most are essentially negative, one trial suggested that donepezil might be effective for the treatment of MCI for a limited period of time. Implications of MCI for clinical practice and future research directions are discussed.
INTRODUCTION
In recent years there has been a virtual explosion of information on the early diagnosis of a variety of dementing disorders, and the construct of mild cognitive impairment (MCI) has come to represent an incipient stage of dementia. It is presumed that for most degenerative conditions there is almost certainly a phase of ''being clinically intermediate. ' ' That is, by definition, degenerative diseases begin insidiously and progress very gradually. Therefore, it is quite plausible that there is a stage early in the development of a degenerative disorder in which a person might be ''partially symptomatic. '' Applying this reasoning to Alzheimer's disease (AD), the existence of a prodromal phase in the disease process, during which a person might be slightly forgetful but have preservation of other cognitive capacities and functional abilities, is quite likely. This stage in the AD process has become known as MCI (Petersen et al, 2001a; Petersen, 2003b) . Later, discussions will classify MCI as a general construct and specific subtypes of MCI as prodromal phases of various diseases, but the general condition is one of an incipient phase of a degenerative disease. An important, but sometimes difficult, distinction should be made between the cognitive changes of aging and MCI as discussed in Case 1-1.
Also, implicit in this discussion is the assumption that the earlier we make the diagnosis of a degenerative disease, the better. With the aging of the worldwide population (Sloane et al, 2002) , the evolution of degenerative dementias is becoming a potential crisis. Therefore, the major strategy for dealing with these disorders involves delaying the onset and/or the progression. Early diagnosis of these conditions then becomes paramount in trying to prevent subsequent disability when effective therapies become available.
HISTORY
Cognitive changes of aging have been the topic of study for decades. Most of these discussions have revolved around cognitive changes associated with the extremes of normal aging such as benign senescent forgetfulness, age-associated memory impairment (AAMI), aging-associated cognitive decline (AACD), and late-life forgetfulness (Gauthier et al, 2006) . For example, AAMI was popular in the 1980s and referred to persons who had memory impairment relative to the memory performance of younger individuals that was believed to be a manifestation of aging. The term AACD was used to expand this construct to include other cognitive domains besides memory but, once again, was intended to refer to the extremes of normal aging.
In contrast, MCI is meant to refer to an abnormal process, likely the prodromal stages of a dementing condition and, as such, is fundamentally different from the extremes of normal aging. Subsequent discussions in this chapter will include several references to the distinction between MCI and normal aging.
EPIDEMIOLOGY
Studies on the epidemiology of MCI are beginning to emerge. Because MCI has been relatively recently described, many previously designed epidemiologic studies were already underway without having incorporated MCI criteria. Consequently, a good bit of variability exists in the literature with respect to precise figures. Table 1-1 shows some of the studies that retrofitted MCI criteria to ongoing longitudinal studies, as well as newer studies in which MCI criteria were built into the study prospectively. Several cohort studies that have used MCI criteria prospectively are also included because they have helped to clarify some of the ongoing issues (Lopez et al, 2003) .
In general, the best studies are the prospectively designed cohorts that include current MCI criteria. These studies reveal prevalence rates of 12% to 18% among nondemented subjects aged over 65 years and somewhat lower rates when the entire population, including demented subjects, serves as the denominator (Bennett et al, 2002; Unverzagt et al, 2001 ). As will be discussed later, these figures depend somewhat on the specific subtype of MCI and the implementation of the criteria. For example, when a neuropsychological algorithm is used to define MCI, the figures are quite variable (Ritchie et al, 2001 ). This reflects the arbitrary nature of the selected neuropsychological instruments and the cutoff scores used. If a single neuropsychological memory test with one cutoff score is used to define memory impairment (and, by inference, MCI), the results are quite variable (Larrieu et al, 2002) . In addition, some of the studies describe instability of the construct over time, whereas, in fact, the instability demonstrated was due to the time-to-time variability of neuropsychological testing rather than the construct of MCI (Larrieu et al, 2002; Ritchie et al, 2001) . Hence, there are many methodological considerations in interpreting the epidemiologic data on MCI. In summary, the data in Table 1 -1 indicate that the overall prevalence of MCI is probably in the 12% to 15% range among individuals aged 65 years and older, and the incidence rates are in the 1% per year range, similar to those of AD.
CLINICAL CHARACTERIZATION

Original Criteria
The original criteria developed for MCI were centered on memory impairment. As is shown in Table 1 -2, these criteria were designed to characterize the early stages of an AD-like process, hence, the emphasis on memory . However, as the field has expanded, it has become apparent that not all patients with MCI evolve to AD. Therefore, the criteria have been expanded to include many types of intermediate cognitive impairment that may be precursors to a variety of dementing disorders. An international conference on diagnostic criteria was convened in Stockholm in 2003 to expand the criteria to include other forms of cognitive impairment and to help translate these findings for primary care practitioners, who will be most likely to initially encounter persons with intermediate degrees of cognitive impairment (Petersen, 2004; Winblad et al, 2004) . Figure 1 -1 shows the current diagnostic algorithm that is being used by the National Institute on Aging-sponsored Alzheimer's Disease Centers Program and the Alzheimer's Disease Neuroimaging Initiative to diagnose MCI (Mueller et al, 2005) .
Diagnosis
The initial criteria used to diagnose amnestic MCI (aMCI) are shown in Table 1 -2. They are still valid, but the construct has been expanded as is apparent in Figure 1 -1. The flowchart in Figure 1 -1 gives the option to the clinician to use various degrees of information to make the diagnostic decision (Table 1-3) . As illustrated, the first criterion involves a cognitive concern on the part of the patient or an informant (Daly et al, 2000) . If the patient or informant has a concern about the patient's cognition, the physician must then determine whether the person's cognitive function is normal or compatible with dementia. Clinicians can use the combination of history, mental status examination, neuropsychological testing, or any other additional information that may be available to them to make this determination. Based on this assessment, if the clinician believes the patient to be neither normal nor demented, and, according to the history obtained from the subject and informant, there appears to have been a decline in cognitive function with preservation of most daily activities, then the patient can be designated as having MCI. Again, When the clinician has completed describing the patient's symptom complex, the next step involves determining the etiology of the symptoms.
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Case 1-2
A 68-year-old retired teacher has been becoming increasingly forgetful over the past year. Although the demands on this man have been reduced in retirement, he is still having difficulty recalling details of recent events. He is impaired in trying to recall recent important information such as doctors appointments, luncheon engagements, and golf tee times with his friends. His family has been noting that he is forgetting information that he formerly would not have forgotten. He seeks your help with this problem.
On examination, he scores 26/30 on the Mini-Mental State Examination, missing recall of all three words as well as the day of the week. The remainder of his neurologic examination is normal. He is concerned but not depressed. His MRI scan shows mild atrophy of the hippocampal formations bilaterally, but the scan is otherwise normal, including an assessment of the white matter. He has no medical problems that are out of control. Neuropsychological testing showed preserved general intellectual skills, with intact attention, concentration, language, and visuospatial functions. On learning and memory tasks, he had some difficulty learning new material but had a prominent deficit in delayed recall of the words on the list from the Auditory Verbal Learning Test and the story recall on the Wechsler Memory Scale III Logical Memory subtest.
Comment. This retired teacher likely has aMCI of a degenerative etiology. He has a concern about his memory, and the problem has had a gradual onset and slow progression. His other cognitive skills are intact, and he does not have a significant functional impairment. These two factors imply that he does not meet criteria for dementia. This may represent the earliest clinical manifestations of a degenerative disorder such as AD.
KEY POINT:
A When the clinician has completed describing the patient's symptom complex, the next step involves determining the etiology of the symptoms. This is done in a similar fashion to making the diagnosis of dementia (Figure 1-2) . That is, typically a clinician will decide that a patient meets criteria for dementia and then determines the subtype of dementia, eg, Is it degenerative likely leading to AD, or might there be a vascular component that suggests vascular cognitive impairment? This type of determination is typically done based on the history from the patient and the informant, laboratory testing for other causes of cognitive impairment, and perhaps neuroimaging studies. When these evaluations are completed, the clinician determines whether the MCI syndrome is degenerative (gradual onset, insidious progression), vascular (abrupt onset, vascular risk factors, history of strokes, TIAs), psychiatric (history of depression, depressed mood, or anxiety), or secondary to concomitant medical disorders (congestive heart failure, diabetes mellitus, systemic cancer). By combining the clinical syndrome with the presumed cause, the clinician can make a reliable prediction about the outcome of the MCI syndrome as is shown in Figure 1 -2.
Outcome
In general, when the criteria outlined in A 72-year-old retired car salesman was noting difficulties while driving. He could remember the instructions of the route he was to take but had difficulty making perceptual decisions regarding turning into the proper lanes and keeping his car in proper perspective relative to the other vehicles on the road. These are relatively subtle difficulties at this time but represent a change for him. His memory was normal but he found himself being easily distracted in conversations. His wife commented on his driving and noted that at night he had a tendency to sit up in bed and act as if he were selling a car. On one occasion, he almost struck her while gesturing with his arms. He comes to you concerned about these changes in his behavior.
On examination, he scores 28/30 on the Mini-Mental State Examination, demonstrating an inability to copy a pentagon. He has slight masking of his face, but otherwise the neurologic examination is normal. His MRI is unremarkable and in particular shows no medial temporal lobe atrophy. Language skills are normal, and he is not depressed. Neuropsychological testing shows normal learning and recall as well as naming and comprehension. On the Trail Making Test, Part A, he is slow, and he becomes confused while doing Part B. His visuospatial skills are quite poor, with significant distortions in copying two-and three-dimensional objects as well as poor reproduction of a clock. A polysomnogram demonstrates a REM behavior disorder.
Comment. This is an example of naMCI of the multiple domain type with impairments in visuospatial skills and attention and concentration. His memory and language functions are normal. The history is suggestive of a degenerative course, and his MCI may represent the prodromal form of dementia with Lewy bodies. He has mild extrapyramidal features and a REM behavior disorder, but he is not demented. As such, this could be the forme fruste of dementia with Lewy bodies, but at this point in time, he has naMCI. presumed degenerative etiology (pre-AD MCI) progress to dementia, usually AD, at a rate of 10% to 15% per year Petersen et al, 2005) . There is, however, variability in the literature on this rate, which reflects, in part, the implementation of the criteria. For example, in some of the epidemiologic studies discussed previously, particularly in those that retrofitted neuropsychological criteria to existing databases, the figures are variable, with some studies reporting lower progression rates (Aggarwal et al, 2005a; Daly et al, 2000; Gauthier et al, 2006) . In the large clinical trials on MCI, to be discussed later, the progression rates varied from 5% to 16% per year (Petersen et al, 2005) . As will be discussed, there are a variety of possible explanations for this variability. Nevertheless, in spite of this, all of these progression rates far exceed the population incidence figures for AD of 1% to 2% per year. So, in counseling patients, a figure of 10% to 12% per year is probably a reasonably accurate prediction.
As mentioned, lower rates of progression have been described in some of the older epidemiologic studies, but in a large prospectively designed trial from Germany, MCI subjects diagnosed using the criteria in Figure 1 -1 progressed to dementia at approximate rates of 7.2% to 10.2% per year (Busse et al, 2006) . Some subjects improved from MCI to normal (approximately 5% per year), but another subset improved and subsequently declined again, implying instability in the clinical course as one progresses to dementia. The vast majority of dementia cases were believed to be AD.
As more longitudinal studies emerge, it is probably most reasonable to inform patients that those who meet criteria for MCI, particularly aMCI of a degenerative cause, will likely progress to dementia, mostly AD, at a rate of 10% per year. It is also important to note that a small fraction of these subjects will improve and that some will remain stable for many years.
In general, in a typical clinical neurology practice setting, given the likelihood that these patients are presenting with a cognitive concern, if patients meet the criteria for aMCI, the progression rate is likely to be in the 10% to 15% per year range. However, in community studies, where a more heterogeneous patient population exists, the rates may be lower, perhaps in the 8% to 10% per year range.
Predictors of Progression
A major question in the field of MCI research concerns the ability to predict which MCI subjects are more likely to progress to dementia or AD more rapidly than others. From a clinical trials perspective, those individuals designing studies for potential therapeutics would like to stratify subjects to maximize the likelihood of progression to AD over a reasonable period of time. At present, potential candidates for predicting progression are (1) clinical severity, (2) MRI hippocampal volumes, (3) APOE4 carrier status, (4)
CSF biomarkers, and possibly, (6) amyloid imaging ( Table 1-4) . Clinical severity. It is apparent that patients who have a more severe memory impairment are more likely to progress more rapidly than those with less severe memory impairment, and this may have accounted for some of the variability in the clinical trials to be discussed later. In any event, those patients who have greater memory impairment and probably those who have aMCI of the multiple domain type will progress more rapidly than those with less severe or single domain impairment. A recent study from the Mayo Clinic indicated that those patients with aMCI of the multiple domain type actually had poorer survival than patients with aMCI-single domain (Hunderfund et al, 2006) (Figure 1-3) .
MRI volumetric studies. Probably more data on the progression of outcome are available for MRI than for other biological parameters. In general, hippocampal atrophy (see ''Neuroimaging in Dementia'' chapter) has been a prominent and important predictor of subsequent progression to dementia and AD from MCI (Jack et al, 1999) (Figure 1-4) . More recently, other structural magnetic resonance measures, such as entorhinal cortex volume, whole brain volume, and ventricular volume, have also been shown to be useful ( Jack et al, 2005) . Recent evidence demonstrates that subjective visual assessments of the hippocampal formation may also be useful (DeCarli et al, 2007) .
APOE4 status. APOE4 carrier status is a well-known risk factor for the development of AD (Corder et al, 1993) . This has been documented in numerous studies worldwide. A decade ago it was demonstrated that APOE4 carrier status was also predictive of progression from MCI to AD, and several subsequent studies have replicated these findings in other 23 (Aggarwal et al, 2005b; Petersen et al, 1995; Petersen et al, 2005) . Therefore, this is an important adjunct to the clinical diagnosis of aMCI in predicting the rate of progression; yet it is still not recommended for clinical use for a variety of reasons (Farrer et al, 1997) .
CSF biomarkers. A recent large study on the potential use of CSF tau and Ab for the prediction of progression from MCI to AD has indicated that these markers can be very helpful in predicting who is going to progress more rapidly (Hansson et al, 2006 Neuroimaging Initiative (Mueller et al, 2005) , currently underway. Other biomarkers are less well studied, but several more easily obtained markers, such as plasma Ab, may also be useful (Graff-Radford et al, in press).
FDG-PET. Some investigators believe that metabolic brain changes may precede structural changes and are likely to be earlier indices of incipient pathologic processes. Therefore, they might be useful in evaluating patients with MCI. The best-studied metabolic marker for AD has been FDG-PET, and several studies have indicated that FDG-PET patterns consistent with evolving AD may be prominent in persons who are genetically predisposed to develop AD but are normal at present (Reiman et al, 1996; Small et al, 1995) . Perhaps the best studies on MCI are those that have been performed in Italy, and these studies indicate that AD patterns of PET at the MCI stage are predictive for progression to AD (Drzezga et al, 2005) . Although intuitively reasonable, these studies also need to be expanded before this technique can be recommended for clinical adoption.
Molecular imaging. The newest imaging techniques for predicting progression in MCI have involved molecular techniques designed to identify the underlying pathology in vivo. The most popular technique used thus far has involved imaging amyloid deposition in the brain using the Pittsburgh Compound B (PIB) (Klunk et al, 2004) . Early studies have demonstrated its utility at discriminating among normals, MCI, and AD patients. Few longitudinal data are available regarding the outcome of patients with MCI. Early data, however, indicate that some patients with MCI have PIB retention patterns that are quite similar to those of patients with fully developed AD, whereas some have no retention, reminiscent of normal subjects. There is, however, a third group that also has an intermediate degree of retention, much like that seen in the clinical profile of patients with MCI.
Another tracer, FDDNP, has been developed at the University of California, Los Angeles, and this compound likely labels neuritic elements in the brain, including both neuritic plaques and neurofibrillary tangles (Small et al, 2006) . As such, this compound is less specific for AD but may be more sensitive at imaging the total pathologic burden. Once again, data are very preliminary and longitudinal studies need to be completed to assess the utility of this tracer.
Neuropathology
An important question concerning MCI revolves around its underlying neuropathologic substrate. The issue is most relevant concerning the aMCI subtype of presumed degenerative etiology or the pre-AD MCI type. Some investigators contend that, at this stage of clinical progression, the neuropathologic substrate of AD is already in place, and therefore, we should label these patients as having clinical AD (Markesbery et al, 2006) . A study from Washington University claimed that AD exists neuropathologically at this point, but two issues need to be discussed regarding these data. First, investigators at Washington University do not use the clinical designation of MCI and likely see patients who are clinically more advanced than MCI. Hence, not surprisingly, their neuropathologic data demonstrate AD (Morris et al, 2001 an outcome study, not a cross-sectional study of subjects with mild degrees of cognitive impairment.
A more recent study from the University of Kentucky concluded that patients with MCI also mostly had AD pathology (Markesbery et al, 2006) . However, these investigators acknowledge that their patients may have been more clinically advanced than in other MCI studies and that they were most likely dealing with a very early clinical AD population.
Investigators from the Religious Order Study have demonstrated an intermediate pathology between the neuropathologic changes of normal aging and very early AD (Bennett et al, 2005) . These investigators acknowledge that there is likely a combination of findings, including neurodegeneration and vascular factors, contributing to the clinical picture.
Very recent studies from the Mayo Clinic have shed additional light on this topic. Using the criteria outlined in Figure 1 -1, those patients who died while their clinical classification was aMCI had neuropathologic features intermediate between changes of normal aging and AD . Most of these patients had some form of medial temporal lobe pathology, usually neurofibrillary tangles, but only sparse diffuse plaques in the neocortex (Figure 1-5) . Most of these subjects had a low probability of having AD pathology when staged using National Institute on AgingReagan criteria (Table 1-5).
26
FIGURE 1-5 Typical neuropathology including neurofibrillary tangles and neuritic amyloid plaque in subjects with amnestic mild cognitive impairment. MCI = mild cognitive impairment; AD = Alzheimer's disease. A second study from the Mayo Clinic investigating the outcome of patients with aMCI demonstrated that the vast majority of patients progressed to AD, but more than 20% of the patients had other types of dementing disorders such as dementia with Lewy bodies, frontotemporal dementia, progressive supranuclear palsy, and vascular dementia, although any one of these disorders was quite uncommon (Figure 1-6) (Jicha et al, 2006) . Therefore, while most aMCI cases go on to AD, a certain proportion will be atypical presentations of other conditions. Although one could maximize sensitivity by moving the clinical diagnosis to the MCI stage, one has to be concerned about the risk of sacrificing specificity.
In summary, it appears that the actual pathologic substrate of most patients with aMCI is evolving AD. That is, the full AD neuropathologic spectrum is not present at the MCI stage, but many of its incipient features are evolving (Figure 1-5) . MCI represents a useful clinical entity because it has a reasonably high probability of progressing to AD, but the condition has not sufficiently developed to be labeled as clinical AD.
Clinical Trials
Currently no US Food and Drug Administration (USFDA)-approved treatments are available for MCI. One would not expect there to be an overall treatment indication for MCI anymore than one would expect an overall treatment indication for dementia. As with dementia, the specific subtypes of MCI might be potential drug targets. As we subdivide dementia into its multiple categories such as AD, vascular dementia, frontotemporal dementia, etc, we can similarly divide MCI into various subcategories as shown in Figure 1 -2. Most interest has been paid to the form of aMCI as a potential drug target because this is likely the prodromal state of AD.
In recent years five major drug trials have used compounds being 
KEY POINTS:
A Although most amnestic MCI cases go on to AD, a certain proportion will be atypical presentations of other conditions.
A MCI represents a useful clinical entity because it has a reasonably high probability of progressing to AD, but the condition has not sufficiently developed to be labeled as clinical AD.
A Interest has been paid to the form of amnestic MCI as a potential drug target because this is likely the prodromal state of AD.
considered for the treatment of AD (Table 1-6). These trials have involved 4000 to 5000 subjects worldwide and are now completed. As a whole, they have been somewhat disappointing insofar as none of the trials has been notably positive, with one possible exception (see Petersen, 2003a , for a review). As will be discussed later, there are numerous reasons for this outcome.
Alzheimer's Disease Cooperative Study donepezil and vitamin E trials. Perhaps the most informative trial was performed by the Alzheimer's Disease Cooperative Study (ADCS) (Petersen et al, 2005) . This study involved 69 centers in the United States and Canada and enrolled 769 subjects with aMCI. The subjects were randomized to one of three treatment groups: donepezil (10 mg per day), vitamin E (2000 IU per day), or placebo. Subjects in all groups received a multivitamin. The subjects were randomized to one of the three treatment groups and followed for up to 3 years with evaluations every 6 months. The entry criteria essentially included those outlined in Table 1 -1 for MCI, and the primary outcome measure was clinical progression to AD. The entry criteria were operationalized by requiring the subjects to have a Mini-Mental State Examination score of 24 or greater and an educationadjusted delayed recall score on one paragraph from the Wechsler Memory Scale-Revised Logical Memory subtest. These criteria ensured that the subjects were sufficiently memory impaired to be close to transitioning to AD but did not yet meet criteria for dementia.
The study had projected that the progression rate for the aMCI subjects would be 10% to 15% per year and was powered to reduce the rate of progression by 33%. The results indicated that neither of the two active treatment arms was able to reduce the risk of progressing to AD over the entire 36 months. However, donepezil reduced the risk of progression to AD for the first 12 months of the study in all subjects and up to 24 months in the APOE4 carrier subgroup. This latter group was not trivial because 76% of the 214 conversions encountered in the trial were APOE4 carriers. Therefore, a treatment effect for donepezil was noted for up to 12 to 24 months. No treatment effect was noted for vitamin E. Secondary cognitive measures essentially corroborated the primary outcomes; that is, several cognitive measures of the individual cognitive domains as well as indices of global function demonstrated a treatment effect in the donepezil group for 12 to 18 months and were more exaggerated in the APOE4 carriers. The patients with aMCI progressed to AD at a rate of 16% per year in this study, quite similar to what was projected. Of the 214 conversions to dementia, 212 were ultimately diagnosed with possible or probable AD, indicating that the aMCI criteria were quite specific.
The clinical recommendations from this trial were somewhat conservative but important for patient interactions. The authors recommended that, although donepezil could not be recommended for the treatment for aMCI based on these data, the results did suggest that clinicians should have discussions with patients on an individual basis. That is, the consideration for the use of donepezil in MCI might be individualized, and again, although there is no USFDA-approved treatment for MCI, this off-label use could be considered based on these data. The second recommendation pertained to APOE. Here again, no recommendation is made for genotyping patients with aMCI, but the interesting results in this study will lead to further research. These data raised the question as to whether patients should be genotyped to enhance the likelihood of a clinical progression at an earlier stage in the disease process. However, because many consensus panels have argued against using APOE4 genotyping prior to the diagnostic stage of AD, this study agreed with those recommendations. Finally, this study is important because it was the first demonstration of any intervention's possible delay in the onset of clinical AD.
Rivastigmine trial. Another large study initiated about the same time as the ADCS trial used another acetylcholinesterase inhibitor, rivastigmine (Feldman et al, 2004) . This study involved 1018 subjects with aMCI and also assessed progression from aMCI to AD over the course of 2 years. This study had many of the same features as the ADCS trial but encountered difficulties with the implementation of the criteria. It should be noted that this study was conducted in 14 countries using multiple languages and translations of the neuropsychological instruments. Consequently, this study had a lower conversion rate than expected and had to be extended to 4 years to achieve an adequate number of events. During that time period, 17.3% of the rivastigmine subjects progressed to AD while 21.4% of the placebo subjects progressed. This difference was not significant but was in the appropriate direction. This study used a composite neuropsychological battery, and no dramatic change occurred in these measures over the time course of the subject. This study had included approximately 41% APOE4 carriers and used different instruments for the inclusion criteria. The investigators also speculated that a significant number of patients with depression may have been included in this trial, which may have contributed to the lower than expected conversion rate of 9% per year. However, once again, in spite of the lower than expected conversion rate, almost all of the patients who progressed to dementia were ultimately diagnosed with AD.
Rofecoxib trial. Another large trial of patients with aMCI was conducted with the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib . This trial, involving 1457 subjects in a randomized, placebo-controlled, double-blind study of aMCI, assessed the rate of progression to AD over 2 years. Once again, the progression rate of the patients from aMCI to AD was lower than expected, causing the
A planned 2-year study to be extended to 3 to 4 years. This study experienced an annual conversion rate to AD of 6.4% for the rofecoxib group compared with 4.5% for the placebo subjects, and this difference was actually statistically significant (P=.011) in favor of the placebo group. The authors indicated, however, that the secondary cognitive measures did not corroborate the primary outcome and consequently tended to dismiss the significance of the finding in favor of placebo. It is uncertain whether this does in fact mean that the COX-2 inhibitor yielded a more rapid progression to AD or whether it was simply a statistical finding. The authors noted that several factors tended to lead to a greater rate of progression to AD, including lower Mini-Mental State Examination score, APOE4 carrier status, age, gender, and prior use of ginkgo biloba. In fact, when these measures were entered into a multivariate prediction model, the previously noted primary outcome was no longer present. It is worth noting that in this trial the investigators modified the memory inclusion criteria to accept a lesser degree of impairment in order to enhance recruitment. It is uncertain whether this led to a more mildly affected group of patients or not, but it is possible that this factor contributed to the lower conversion rate.
Galantamine trials. Finally, two studies assessing the progression from aMCI to AD used the acetylcholinesterase inhibitor, galantamine (Gold et al, 2004) . These international studies assessed the rate of progression from aMCI to AD measured by progression on the Clinical Dementia Rating scale from 0.5 to 1.0. It may be important to note that this study did not use clinical criteria for AD as a conversion point; rather, it assessed progression simply by using the Clinical Dementia Rating. This may have resulted in some lost sensitivity because patients can progress from aMCI to AD and remain at the Clinical Dementia Rating scale level of 0.5. The two trials included a total of 2048 subjects, and the proportion of subjects who were APOE4 carriers was 43%. The effect of galantamine was not significant in either of the trials, but there was a trend toward reduction in the rate of progression in favor of galantamine, with 13% of galantamine-treated subjects and 18% of placebo-treated subjects progressing over 2 years in one trial. In the second trial, 17% of the galantamine group progressed, whereas 21% of the placebo group progressed, but neither of these trials reached statistical significance. In this study MRI scans were performed on many of the patients, and there was a suggestion that galantamine may have reduced the rate of whole brain atrophy over the 2-year period. Consequently, although no significant treatment effects were noted in these trials, there was a suggestion of drug effect, and this may have been corroborated by a reduction in atrophy as assessed by MRI volumetric measures.
Summary of clinical trials. Taken together, these trials have produced some important findings. The most notable shortcoming in the trials, in addition to the lack of efficacy, was the variable rate of progression from aMCI to AD. In all likelihood, several possible factors probably contribute to this variability, including the subject populations recruited, enrollment procedures, operationalization of the criteria, and primary outcome measures. As noted above, some of the international trials were conducted in multiple countries using multiple languages. As such, the translation of these instruments is a concern, as well as the cultural variability regarding what constitutes dementia and AD, much less aMCI. the clinical judgment of the threshold for AD can vary widely among cultures because the functional requirement for the diagnosis of dementia may be very culture-specific. Therefore, if one extrapolates these problems to the clinical context of making the rather subtle diagnosis of aMCI, these cultural differences are likely to be magnified. Although it was ambitious for the investigators to undertake these studies in a multinational setting, they may have encountered insurmountable logistical difficulties.
The second factor that likely influenced the results of these studies involved the variable APOE4 carrier rates in the studies. This also likely reflected the recruitment procedures. Because APOE4 is a strong predictor of progression to AD, this likely influenced the outcome of several of the studies. It is noteworthy that the ADCS donepezil/ vitamin E trial had a 55% APOE4 carrier rate. As noted above, the studies used slightly different implementation procedures for the memory criteria. Although seemingly innocuous, the various cutoff scores that were used for inclusion in the trials may have had a significant impact on the ultimate composition of the study groups. For example, if relatively milder degrees of impairment were used for determining aMCI, it is quite possible that patients with very mild aMCI, and possibly normal subjects, may have been included in the treatment groups, thereby resulting in lower than expected conversion rates.
The variability in the primary outcome measure may have been an additional factor. As noted above with respect to the cultural differences in making the clinical diagnosis of AD, the studies varied as to how the primary outcome measure was operationalized. One of the studies used the Clinical Dementia Rating as the outcome, whereas others used the clinical judgment of the investigators to make the diagnosis of AD. Again, because we are dealing with a subtle phenomenon in the incipient stages of the AD process, these differences in implementation criteria may have been significant. In summary, although there was a great deal of variability in these studies, there were also several notable factors concerning the construct of aMCI. While the progression rate varied from approximately 5% to 16%, all of these rates are vastly higher than the population incidence rate for AD of 1% to 2%. That is, even the ''least successful'' trial doubled or tripled the progression rate for the normal population. Clearly, the ADCS rate of 16% per year exceeded the population rate by severalfold. As such, although the treatments chosen were not demonstrated to be effective, the study designs did yield an enriched population for evaluating compounds that may have important treatment implications for AD. As treatments for disease modification become available, the aMCI subject group might be an appropriate group of individuals to study. Certainly, lessons from the aMCI trials would contribute to an enhanced group of patients that might very well progress at an accelerated rate, providing an excellent clinical substrate for testing compounds designed to modify the underlying disease process.
CLINICAL UTILITY
Ultimately, the clinical utility of the construct of MCI will be determined by practicing clinicians. That is, if the practicing clinician believes that MCI is a useful construct with respect to clinical contacts with patients, then it will persist. Evidence indicates that many clinicians are able to identify a subset of patients in their practices who have the ''partial symptoms'' of a dementing disorder but are not sufficiently impaired to
KEY POINTS:
A deserve the label of dementia or AD. Again, as discussed above, most of the literature pertains to the aMCI subtype of a degenerative etiology, which is likely prodromal AD. As such, most of the remarks will be confined to that clinical subtype.
The American Academy of Neurology has endorsed the construct of MCI in an evidence-based medicine practice parameter paper published in Neurology in 2001 (Appendix C) (Petersen et al, 2001b) . In that paper, the authors concluded that sufficient evidence is available to encourage clinicians to identify and evaluate patients in their practices who have the clinical features of MCI. These individuals are at an increased risk of developing dementia in the future and warrant appropriate counseling. Perhaps treatments will become available for these patients in the future. Since the publication of this practice parameter, the literature on MCI has vastly increased, and consequently, this practice parameter will likely be updated in the near future.
In all likelihood, with the aging of America, patients who are presenting with subtle cognitive concerns will increase dramatically in clinical practice. As such, practicing clinicians will need a diagnostic framework with which to evaluate, classify, and ultimately guide treatment of these individuals. As the ''baby boomers'' age into the period of risk for AD, our patients have growing concern that incipient cognitive difficulties are emerging. Again, if one accepts the premise that individuals who ultimately develop a degenerative dementia such as AD pass through a stage of partial symptoms, then the construct of MCI becomes quite significant.
It should be noted, however, that these diagnostic classifications are arbitrary. Certainly, in the course of evolving AD, everyone agrees that arbitrary distinctions between categories such as MCI and clinically probable AD are artificial. Nevertheless, this type of terminology is important and useful because we need to communicate with our patients and with each other. It is in this vein that the construct of MCI has been adopted by many clinicians. Because the diagnostic label of dementia or AD has significant social implications, the clinical designation of aMCI can be quite useful in characterizing people who do not meet the fully developed criteria for AD.
What does the clinician tell a patient with MCI? This is a reasonable question and deserves some attention. It appears appropriate to discuss the evolving nature of the construct of MCI with patients. That is, while the criteria are solidifying, there certainly remains discussion in the literature regarding the precise characterization. Nevertheless, if a patient fulfills criteria outlined in Figure 1 -1 and the symptoms are felt to be due to a degenerative process, then the clinician can tell patients that they have a 10% to 15% per year risk of progressing to clinically probable AD. To the extent the patient deviates from the criteria, one can adjust this prediction upward or downward. For example, if you know the person is an APOE4 carrier (keeping in mind that APOE4 testing is not recommended in this clinical situation) and the person has atrophic hippocampal formations on MRI, this person might be at a greater risk of progressing more rapidly. Alternatively, if no family history of a dementing disorder exists, the person is not an APOE4 carrier, and the medial temporal lobe structures look reasonably normal on MRI, one may predict that the individual will not progress rapidly. Of course, the best tool for making this determination is seeing the patient on a regular basis, perhaps From a treatment perspective, the clinician can consider the ADCS trial. For example, if a patient were a 66-yearold business person who wanted to continue to function in the work environment, treatment with donepezil at an earlier stage might be warranted. Alternatively, if the patient were a 72-year-old retired person who largely engaged in leisure activities, the forgetfulness produced by the aMCI might be less bothersome. In this instance, one might defer treatment until signs of greater impairment evolved.
It is often helpful to counsel the patients on the implications of a diagnosis of MCI. While the patient is cognitively competent, it might be time to engage in planning for the future, including financial issues, retirement, living arrangements, etc. As for pharmacologic recommendations, the USFDA has approved no drugs for the treatment of MCI. Nonetheless, as discussed above, one certainly could consider the use of a cholinesterase inhibitor at this stage if the person and the physician wanted to be aggressive at treating the symptoms at this stage in the disease process. Alternatively, one could defer the use of cholinesterase inhibitors until the patient became more impaired. In any event, many physicians are recommending lifestyle modification to try to minimize the rate of progression, although the data here are soft. Frequently, physicians will recommend to the patient that the patient remain physically active, intellectually engaged, and socially active and will encourage the patient to follow a heart-healthy diet. Finally, it is useful to inform the patient that this is a rapidly evolving area of investigation and it is important for the patient to remain in touch with the physician and to keep current with literature on the topic.
FUTURE DIRECTIONS
Because the construct of MCI is relatively new, it is undergoing further revision. Certainly not all individuals have embraced the concept, but it has become useful in many areas of clinical practice. It is currently being considered for inclusion in the next revision of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (Petersen and O'Brien, 2006) . Its ultimate utility will rest with the practicing clinicians.
From a research perspective, however, efforts are underway to increase the specificity of prediction of outcome of subjects with aMCI. As mentioned, it is likely that those subjects who are APOE4 positive and have atrophic hippocampi on MRI will progress more rapidly. These considerations may also improve the specificity of the outcome. Additional measures being investigated include FDG-PET markers of progression as well CSF biomarkers, particularly for tau and Ab. In addition, some of the newer molecular imaging techniques may play a role in predicting the progression of aMCI in the future. Studies are underway to evaluate the utility of PIB for amyloid imaging or FDDNP as a means of imaging neuritic pathology more widely. The utility of these measures remains to be seen, but ultimately, it is likely that a combination of these factors may be useful in predicting the outcome of aMCI.
In the final analysis, there will likely be two levels of use of MCI criteria. First, for the practicing clinician, the clinical criteria, such as those outlined in Figure 1 -1, will probably be most useful. These criteria, when combined with the suspected etiology as outlined in Figure 1 -2, will suffice to suggest the likely outcome of patients. For the most part, patients with aMCI of a degenerative etiology will progress to AD. However, there is likely to be a second level of use of the criteria involving augmentation of the criteria
KEY POINTS:
A It is often helpful to counsel the patients on the implications of a diagnosis of MCI. It might be time to engage in planning for the future, including financial issues, retirement, living arrangements, etc.
A Frequently physicians will recommend that the patient remain physically active, intellectually engaged, and socially active and will encourage the patient to follow a heart-healthy diet.
A It is likely that patients with amnestic MCI who are APOE4 positive and have atrophic hippocampi on MRI will progress more rapidly.
with various technological measures (genotyping, MRI volumetric measurements, FDG-PET, CSF biomarkers, and molecular imaging techniques). These will largely be restricted to research settings initially but may filter into practice at tertiary care centers for the evaluation of difficult cases.
In summary, the construct of MCI has served a useful purpose in sensitizing the clinician to the earlier presenting features of many dementing disorders. As shown in Figure 1 -7, MCI can be viewed as a precursor stage of many dementias. Its subtypes likely will differentiate into specific dementia subtypes.
Most of the literature pertains to the aMCI subtype, and this construct has been useful in predicting who is likely to develop clinically probable AD in the future. As therapies evolve in the field, it is likely that these treatments may be applied to populations with various forms of MCI in an attempt to try to treat the disorders at an earlier point in the disease process. Ultimately, of course, we would like to prevent these disorders by identifying individuals who are at risk for developing these diseases but are still clinically normal. This would be an ideal goal for the application of this research. This paper documents the importance of APOE4 carrier status in predicting progression to incident Alzheimer's disease (AD).
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FIGURE 1-7 Characterization of mild cognitive impairment preceding the diagnosis of dementia with subsequent differentiation into dementia subtypes. MCI = mild cognitive impairment; NOS = not otherwise specified. 
KEY POINT:
A The construct of MCI has served a useful purpose in sensitizing the clinician to the earlier presenting features of many dementing disorders. Ultimately, we would like to prevent these disorders by identifying individuals who are at risk for developing these diseases but are still clinically normal.
